Horm Metab Res 2005; 37(2): 79-83
DOI: 10.1055/s-2005-861171
Original Clinical
© Georg Thieme Verlag KG Stuttgart · New York

Effect of 5-Campestenone (24-methylcholest-5-en-3-one) on Zucker Diabetic Fatty Rats as a Type 2 Diabetes Mellitus Model

R.  Konno1 , Y.  Kaneko1 , K.  Suzuki1 , Y.  Matsui2
  • 1Technoflora Co. and Synthetic Organic Chemistry Laboratory, RIKEN, Japan.
  • 2Nihon Bioresearch Inc, Japan
Further Information

Publication History

Received 6 April 2004

Accepted after revision 11 August 2004

Publication Date:
21 March 2005 (online)


We examined the therapeutic effects of dietary exposure to 5-campestenone (24-methylcholest-5-en-3-one), an enone derivative of campesterol, in Zucker diabetic fatty (ZDF) rats, an animal model of type 2 diabetes mellitus. Dietary 0.6 % exposure to 5-campestenone caused marked reduction in hemoglobin A1c (HbA1c), plasma total cholesterol, triglycerides and non esterified fatty acid (NEFA). In particular, plasma triglyceride levels were reduced in the 0.6 % 5-campestenone-fed group to about 25 % of that in the control group. In the oral glucose tolerance test (OGTT) at three and seven weeks after the beginning of treatment, 5-campestenone limited the rise of blood glucose levels by oral administration of glucose dose-dependently. Amounts of adipose tissue in the retroperitoneum and periepididymal area as well as abdominal subcutaneous fat were significantly decreased in animals fed 0.6 % 5-campestenone. The blood leptin concentration on the final day of feeding was significantly in animals administered 5-campestenone. No obvious anomaly due to consumption of 5-campestenone was detected in necropsy or clinical observations.


R. Konno

Technoflora Co. RIKEN

Wako-shi · Saitama · 351-0198 Japan

Phone: +81(48)467-0787 ·

Fax: +81(48)467-1347

Email: rkonno@postman.riken.go.jp